NCT01578954 - Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2012

Primary Completion Date

May 18, 2016

Study Completion Date

May 18, 2016

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Lenalidomide

"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"

Trial Locations (1)

27599

University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center, Chapel Hill